Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 6, 2009, Pages 1191-1199

  McKay, Geoffrey A ^a   Beaulieu, Sylvain ^a   Arhin, Francis F ^a   Belley, Adam ^a   Sarmiento, Ingrid ^a   Parr, Thomas ^a   Moeck, Gregory ^a  

^a Targanta Therapeutics Inc   (Canada)

Author keywords

Bactericidal; Lipoglycopeptide; Resistance

Indexed keywords

DAPTOMYCIN; LINEZOLID; ORITAVANCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 65749111847     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp126     Document Type: Article

References (51)

1. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Int Med 2001; 135: 484-92.
2. Gould IM. The epidemiology of antibiotic resistance. Int J Antimicrob Agents 2008; 32 Suppl 1: S2-9.
3. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85.
4. Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Exp Opin Invest Drugs 2007; 16: 717-33.
5. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: A novel lipoglycopeptide for serious Gram-positive infections. Exp Opin Invest Drugs 2007; 16: 347-57.
6. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infec Dis 2006; 6: 156.
7. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
8. Schwalbe RS, McIntosh AC, Qaiyumi S et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 1996; 40: 2416-9.
9. Mercier RC, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother 1997; 41: 1307-12.
10. Poulakou G, Giamarellou H. Oritavancin: A new promising agent in the treatment of infections due to Gram-positive pathogens. Exp Opin Invest Drugs 2008; 17: 225-43.
11. McKay GA, Beaulieu S, Belley A et al. In vitro time - kill studies of oritavancin against drug-resistant isolates of Staphylococcus aureus and enterococci. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract E-1614, p. 205. American Society for Microbiology, Washington, DC, USA.
12. Arhin FF, Sarmiento I, Belley A et al. Effect of polysorbate-80 on oritavancin binding to plastic surfaces - implications for susceptibility testing. Antimicrob Agents Chemother 2008; 52 1597-603.
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
14. National Committee of Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. NCCLS, Wayne, USA, 1999.
15. FDA. Division of Antiinfective and Ophthalmology Drug Products (HFD-520) - Microbiological Data for Antibacterial Drug Products - Development, Analysis, and Presentation. 2005.
16. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004; 38: 864-70.
17. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. New Eng J Med 2007; 357: 380-90.
18. Moise PA, Sakoulas G, Forrest A et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51: 2582-6.
19. Finberg RW, Moellering RC, Tally FP et al. The importance of bactericidal drugs: Future directions in infectious disease. Clin Infect Dis 2004; 39: 1314-20.
20. Brickner SJ, Hutchinson DK, Barbachyn MR et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J Med Chem 1996; 39: 673-9.
21. Van Bambeke F, Van Laethem Y, Courvalin P et al. Glycopeptide antibiotics: From conventional molecules to new derivatives. Drugs 2004; 64: 913-36.
22. Fetterly GJ, Ong CM, Bhavnani SM et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005; 49: 148-52.
23. Rowe PA, Brown TJ. Protein binding of 14C-oritavancin. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract A-2193, p. 37. American Society for Microbiology, Washington, DC, USA.
24. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
25. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
26. Arhin FF, Sarmiento I, Parr TR Jr et al. Binding of oritavancin to surfaces impacts choice of vessels for oritavancin in vitro assays. In: Abstracts of the Fifty-eighth Annual meeting of the Canadian Society of Microbiologists, Calgary, Alberta, Canada, 2008. Abstract B1, p. 41. Canadian Society of Microbiologists, Ottawa, Ontario, Canada.
27. Moellering RC. Linezolid: The first oxazolidinone antimicrobial. Ann Int Med 2003; 138: 135-42.
28. Eagle H, Musselman AD, Fleischman R. The action of bacitracin and subtilin on Treponema pallidum in vitro and in vivo. J Bacteriol 1948; 55: 347-58.
29. Eagle H, Musselman AD. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948; 88: 99-131.
30. Baltch AL, Smith RP, Ritz WJ et al. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1998; 42: 2564-8.
31. Babalola CP, Patel KB, Nightingale CH et al. Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities. Int J Antimicrob Agents 2004; 23: 343-8.
32. Hershberger E, Aeschlimann JR, Moldovan T et al. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. Antimicrob Agents Chemother 1999; 43: 717-21.
33. Belley A, Neesham-Grenon E, Arhin FF et al. Assessment of the synergistic effects of oritavancin tested in combination with other antimicrobial agents against Staphylococcus aureus by time-kill methodology. Antimicrob Agents Chemother 2008; 52: 3820-2.
34. Cafini F, Aguilar L, Gonzalez N et al. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 2007; 59: 1185-9.
35. Rybak MJ, Hershberger E, Moldovan T et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-6.
36. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.. J Antimicrob Chemother 2006; 58: 338-43.
37. Harland S, Tebbs SE, Elliott TS. Evaluation of the in vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J Antimicrob Chemother 1998; 41: 273-6.
38. Goldstein BP, Draghi DC, Sheehan DJ et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007; 51: 1150-4.
39. Lopez S, Hackbarth C, Romano G et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005; 55 Suppl 2: Ii21-4.
40. Biavasco F, Vignaroli C, Lupidi R et al. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997; 41: 2165-72.
41. Kaatz GW, Seo SM, Aeschlimann JR et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998; 42: 981-3.
42. Noviello S, Ianniello F, Esposito S. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci. J Antimicrob Chemother 2001; 48: 283-6.
43. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454-9.
44. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006; 50: 2330-6.
45. Biedenbach DJ, Bell JM, Sader HS et al. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: A SENTRY Program Report (2003-2004). Int J Antimicrob Agents 2007; 30: 143-9.
46. Saravolatz LD, Pawlak J, Johnson L. In vitro activity of oritavancin against CA-MRSA, VISA and daptomycin-non-susceptible Staphylococcus aureus (DNSSA). In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract C1-187, p. 108. American Society for Microbiology, Washington, DC, USA.
47. Boylan CJ, Campanale K, Iversen PW et al. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003; 47: 1700-6.
48. Wasilewski M, Disch D, McGill J et al. Equivalence of shorter course therapy with oritavancin compared with vancomycin/cephalexin in complicated skin/skin structure infections (cSSI). In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract UL-18, addendum p. 7. American Society for Microbiology, Washington, DC, USA.
49. Giamarellou H, O'Riordan W, Harris H et al. Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/ cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI). In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract L-739a, addendum p. 11. American Society for Microbiology, Washington, DC, USA.
50. U.S. National Institutes of Health. A Study for Patients with Complicated Skin and Skin Structure Infections (SIMPLIFI). http://www.clinicaltrials.gov/ct2/show/NCT00514527?term= oritavancin&rank=1 (10 October 2008, date last accessed).
51. Cunha BA, Mickail N, Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007; 36: 456-61.